BRIEF-Eli Lilly Says FDA Expands Label For Zepbound To Include Four-Dose Single-Patient Use KwikPen

Eli Lilly and Company -1.89% Pre

Eli Lilly and Company

LLY

905.03

909.99

-1.89%

+0.55% Pre

Feb 23 (Reuters) - Eli Lilly and Co LLY.N:

  • ELI LILLY: FDA APPROVED LABEL EXPANSION FOR ZEPBOUND (TIRZEPATIDE) TO INCLUDE FOUR-DOSE SINGLE-PATIENT USE KWIKPEN

  • ELI LILLY: ZEPBOUND PATIENTS CAN NOW ACCESS ALL DOSES IN EITHER MULTI-DOSE KWIKPEN OR SINGLE-DOSE VIAL STARTING AT $299 PER MONTH FOR 2.5 MG DOSE

  • ELI LILLY: ZEPBOUND KWIKPEN IS AVAILABLE IN 2.5 MG, 5 MG, 7.5 MG, 10 MG, 12.5 MG, OR 15 MG DOSES


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.